Although ovarian cancer cell lines with ARID1A-deficiency showed some in vitro sensitivities to PI3K/AKT inhibitors [39], no in vivo responsiveness of GC cells with ARID1A-deficiency effectiveness of PI3K/AKT inhibitors has been addressed. Here, AKT1 is linked to gastric cancer.